Diversified Pipeline
Discovered Using Pharma.AI
Discovered Using Pharma.AI
INNOVATIVE AND ACCELERATED INTERNAL DRUG CANDIDATES
- 31Total Number of Programs
- 29Total Number of Targets
- 2Preclinical Candidates Nominated in 2021
- 9Preclinical Candidates Nominated in 2022
Programs below progressed beyond early pre-clinical. Many programs are available under CDA.
Contact bd@insilicomedicine.com for partnering opportunities
Target
Fibrosis
Immunology
Oncology
Other
Stage of development
Discovery
IND-enabling
Phase 1
Phase 2
TARGET X* — Undisclosed target.
EMT, FMT, fibroblast macrophage activation
Idiopathic Pulmonary Fibrosis
(IPF)
(IPF)
Kidney Fibrosis
Immune modulation
Immuno-Oncology
Epigenetics
Immune modulation
ER+/HER2- breast cancer
Solid Tumors
Synthetic lethality
MTAP-/- cancer
Tumor cell proliferation
Solid Tumors
Synthetic lethality
BRCA-mutant cancer
DGKA
Immune modulation
CDK12
Solid Tumors
cMYC
Virus replication
COVID-19
ENPP1
Tumor cell proliferation
Solid Tumors
IPF (Inhalable)
EPO induction and iron utilization
Anemia of Chronic Kidney Disease
Inflammatory Bowel Disease
Mechanism
indication
Epithelial integrity & anti-inflammation
TEAD
Cell proliferation and survival
Solid Tumors
Co-development with Fosun Pharma
US (FDA)
China (NMPA)
Licensed out to Exelixis
COLLABORATIONS
AND PARTNERSHIPS
AND PARTNERSHIPS
The rapid progress of internal pipeline demonstrates the generative-AI driven drug discovery capabilities of our Pharma.AI platform consisting of Biology42, Chemistry42, and Medicine42.
Our collaboration partners can leverage our technology and development capabilities to augment and accelerate their discovery and development initiatives.
Our collaboration partners can leverage our technology and development capabilities to augment and accelerate their discovery and development initiatives.
TARGET X
Target X Inhibitor: Treating Fibrotic diseases of the Lung and Kidney
PHD
Proline Hydroxylase (PHD) Inhibitors: Treatment of Inflammatory Bowel Disease (IBD) and Chronic Kidney Disease (CKD)
QPCTL
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) Inhibitor: Novel cancer immunotherapy for COLD tumors
USP1
Ubiquitin Specific Protease 1 (USP1) Inhibitor for the treatment of BRCA-mutant cancer
MAT2A
Methionine adenosyltransferase 2α (MAT2A) Inhibitor: Treatment of MTAP Deficient Cancer
3CLPro
Orally Available covalent irreversible 3CLPro Inhibitor for the Treatment of COVID-19 and Coronavirus infection
KAT6
KAT6 Inhibitor: Treatment of ER+/HER2- Breast Cancer
DGKA
Diacylglycerol kinase A (DGKA) Inhibitors: Treating solid tumors in combination with checkpoint inhibitors
CDK8/19
Cyclin Dependent Kinase 8/19 (CDK8/19) Inhibitors: Treating Tumors with Deregulated Transcription
CDK12
Cyclin-dependent kinase 12 (CDK12) Inhibitors: Treating Tumors byInduction of BRCAness
ENPP1
Ectonucleotide phosphodiesterase 1(ENPP1) Inhibitors: Treating anti-PD1 antibody resistance cancers
PARP7
213123